Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Treatment of Advanced Prostate Cancer.

Teo MY, Rathkopf DE, Kantoff P.

Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947.

PMID:
30691365
2.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
3.

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K.

Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015. Review.

4.

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment.

Shah H, Vaishampayan U.

Target Oncol. 2018 Dec;13(6):679-689. doi: 10.1007/s11523-018-0611-0.

PMID:
30536163
5.

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations.

Castellan P, Marchioni M, Castellucci R, De Francesco P, Iantorno R, Schips L, Cindolo L.

Ther Clin Risk Manag. 2018 Dec 6;14:2341-2347. doi: 10.2147/TCRM.S159824. eCollection 2018. Review.

7.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
8.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

9.

New and emerging agents for the treatment of castration-resistant prostate cancer.

Higano CS, Crawford ED.

Urol Oncol. 2011 Nov-Dec;29(6 Suppl):S1-8. doi: 10.1016/j.urolonc.2011.08.013. Review.

PMID:
22074657
10.

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):1-6.

11.

Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Suzman DL, Antonarakis ES.

Ther Adv Med Oncol. 2014 Jul;6(4):167-79. doi: 10.1177/1758834014529176. Review.

12.
13.

Emerging Therapies in Metastatic Prostate Cancer.

Sonnenburg DW, Morgans AK.

Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z. Review.

PMID:
29644451
14.

Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Chandrasekar T, Yang JC, Gao AC, Evans CP.

Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02. Review.

15.

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.

de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J; Triptocare LT Study Group.

BJU Int. 2017 Jan;119(1):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23.

16.
17.

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.

Anantharaman A, Small EJ.

Expert Rev Anticancer Ther. 2017 Jul;17(7):625-633. doi: 10.1080/14737140.2017.1333903. Epub 2017 May 31. Review.

PMID:
28532278
18.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
19.

Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.

Miyoshi Y, Yoneyama S, Kawahara T, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, Uemura H.

Urol Int. 2017;99(4):400-405. doi: 10.1159/000477131. Epub 2017 Jun 14.

PMID:
28609769
20.

Current, new and novel therapy for castration-resistant prostate cancer.

Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.

Expert Rev Anticancer Ther. 2013 Jul;13(7):819-27. doi: 10.1586/14737140.2013.811154. Review.

PMID:
23875660

Supplemental Content

Support Center